门诊球囊导管引产与住院前列腺素引产的成本效果分析:OBLIGE随机对照试验的经济学评价
该研究基于多中心随机对照试验OBLIGE,从医疗服务支付方视角比较门诊单球囊导管促宫颈成熟与住院阴道前列腺素引产的成本效果,以避免剖宫产为主要结局。结果显示平均成本差异为-256新西兰元(95%CI -1172至639),避免剖宫产差异为-5.67%(95%CI -11.09至0.07),均未达统计学显著性;当决策者避免一次剖宫产的支付意愿低于4519新西兰元时,球囊导管可能具有成本效果。经产妇亚组中门诊球囊导管为劣势策略(效果更差且成本更高)。
要点
- 门诊球囊导管与住院前列腺素引产的成本差异和避免剖宫产差异均无统计学显著性。
- 当避免一次剖宫产的支付意愿低于4519新西兰元时,球囊导管可能具有成本效果。
- 经产妇亚组中门诊球囊导管效果更差且成本更高,属于劣势策略。
核心结论
- 即时成本不太可能成为门诊球囊导管引产决策的关键因素。
- 未来经济学分析需考虑剖宫产相关的长期成本和临床结局及门诊引产的生活质量影响。
研究设计与样本
- 基于多中心随机对照试验OBLIGE的成本效果分析,比较门诊单球囊导管促宫颈成熟与住院阴道前列腺素引产。
- 采用医疗服务支付方视角,纳入从随机化至产后42天的直接医疗成本(2021年新西兰元)。
- 临床结局来自试验数据收集,医疗资源使用和成本来自常规收集的国家数据。
主要发现
- 自助法重复抽样中,平均成本差异为-256新西兰元(95%CI -1172至639),未达统计学显著性。
- 避免剖宫产差异为-5.67%(95%CI -11.09至0.07),未达统计学显著性。
- 经产妇亚组中门诊球囊导管为劣势策略(效果更差且成本更高)。
关键数值与推荐
- 当决策者避免一次剖宫产的支付意愿低于4519新西兰元时,球囊导管可能具有成本效果。
临床怎么用
- 门诊球囊导管引产的即时成本不太可能成为决策的关键因素。
- 经产妇选择门诊球囊导管引产时需考虑其效果更差且成本更高的劣势。
局限性
- 分析仅考虑至产后42天的直接医疗成本,未纳入剖宫产相关的长期成本、临床结局及门诊引产的生活质量影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Induction of labor is a common obstetric intervention. Numerous methods and protocols for achieving cervical ripening exist, including outpatient management using a balloon catheter. OBJECTIVE: This study aims to perform a cost-effectiveness analysis of the OBLIGE trial, a multicenter randomized controlled trial comparing outpatient single balloon catheter for cervical ripening to inpatient vaginal prostaglandin (PG), using cesarean births avoided as the primary outcome measure. STUDY DESIGN: Using a health service payer perspective, this cost-effectiveness analysis considers the direct healthcare costs (2021 NZ Dollars) from randomization to 42 days post-birth. Clinical outcomes were identified from trial data collection, while healthcare resource use and costs were identified from routinely collected national data. RESULTS: Across bootstraped replicates, the difference in mean costs -$256 (95% CI $-1172 to $639) and caesarean births avoided -5.67% (95% CI -11.09 to 0.07) did not reach statistical significance. These results suggest that balloon catheters may be considered cost-effective where decision makers value a cesarean birth avoided below $4519. Subgroup analysis demonstrates outpatient balloon catheters are dominated (less effective and more costly) among parous women. CONCLUSION: Immediate costs are unlikely to be critical in decisions about the use of outpatient balloon catheter induction of labor. In future economic analyses, consideration of longer-term costs and clinical outcomes resulting from cesarean birth, and any quality of life impacts of outpatient induction, would be important to clarify the cost-effectiveness of this intervention.
引用
- Anderson K, Wise M, Sadler L, et al. Cost effectiveness of outpatient balloon catheter induction of labor compared with inpatient prostaglandin: economic analysis alongside the OBLIGE randomized controlled trial. Am J Obstet Gynecol MFM. 2026. PMID: 42829053. doi:10.1016/j.ajogmf.2026.102142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。